Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.66 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.62 |
| ▸ | BACE1 | P56817 | 2/20 | 0.62 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.62 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 9/20 | 0.59 |
| ▸ | GLP1R | P43220 | 2/20 | 0.58 |
| ▸ | GCGR | P47871 | 1/20 | 0.58 |
| ▸ | GIPR | P48546 | 1/20 | 0.58 |
| ▸ | ECE1 | P42892 | 1/20 | 0.58 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30262077 | 0.95 | TFPI (0.67) | TFPIVIPR1BACE1BACE2VIPR2 | |
| SCHEMBL29893268 | 0.93 | TFPI (0.60) | TFPIVIPR1BACE1BACE2VIPR2 | |
| SCHEMBL31672198 | 0.92 | BACE1 (0.62) | TFPIVIPR1BACE1BACE2VIPR2 | |
| SCHEMBL29453341 | 0.92 | VIPR1 (0.72) | TFPIVIPR1VIPR2KISS1RGLP1R | |
| SCHEMBL30513687 | 0.92 | KISS1R (0.67) | TFPIKISS1R | |
| SCHEMBL29489541 | 0.92 | VIPR1 (0.63) | TFPIVIPR1BACE1BACE2VIPR2 | |
| SCHEMBL30576938 | 0.92 | TFPI (0.68) | TFPIVIPR1VIPR2GLP1RGCGR | |
| SCHEMBL29558454 | 0.91 | TFPI (0.69) | TFPIVIPR1BACE1BACE2VIPR2 | |
| SCHEMBL30699435 | 0.91 | TFPI (0.60) | TFPIVIPR1KISS1RGLP1RGCGR | |
| SCHEMBL30607413 | 0.91 | TFPI (0.66) | TFPIVIPR1BACE1BACE2KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277816-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | PEGBIO CO., LTD. (CN) | 2024-08-22 | — | — | US | claimed |
| US-20240277816-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | PEGBIO CO., LTD. (CN) | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277816-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | IAPP, GIPR, GCG | TFPI 3899/4885VIPR1 256/4885BACE1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.